secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0000950170-23-013272
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio reports positive Phase 1a data for ABI-4334; to partner core inhibitor portfolio, focus on ABI-5366
--------------------------------------------------------------------------------

- ABI-4334 200 mg QD projected >30x protein-adjusted EC50 for cccDNA; half-life supports once-daily dosing.
- Phase 1a safety: mild-to-moderate AEs, no pattern, no clinically significant ECG abnormalities.
- Company will partner core inhibitor portfolio; no further internal clinical development for HBV cure.
- Prioritizing ABI-5366 (genital herpes) with Phase 1 expected H1 2024; second candidate by end of 2024.
- Cash runway extended into Q3 2024 due to reprioritization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023013272/0000950170-23-013272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023013272/asmb-20230418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer